FOLH1 and glioblastoma: A single‐arm phase II study where PSMA‐recognizing antibody‐drug conjugate (ADC) was used in progressive GBM patients (n = 6) following prior treatment with radiation, temozolomide and bevacizumab showed no demonstrable activity in these patients (NCT01856933).